AstraZeneca’s Alexion subsidiary is snapping up a suite of Pfizer’s preclinical gene therapies in a move to expand its toolkit in rare disease R&D. The deal, which the companies said is worth up to $1 billion, was unveiled as AstraZeneca also announced that M…